<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Cellevate</title>
	<atom:link href="https://cellevate.com/feed/" rel="self" type="application/rss+xml" />
	<link>https://cellevate.com/</link>
	<description>Next dimension upstream bioprocessing</description>
	<lastBuildDate>Mon, 30 Mar 2026 08:54:08 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://cellevate.com/wp-content/uploads/2022/04/cropped-Frame-3-32x32.png</url>
	<title>Cellevate</title>
	<link>https://cellevate.com/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Cellevate secures SEK 21.3 Million financing to advance commercialization</title>
		<link>https://cellevate.com/cellevate-secures-sek-21-3-million-financing-to-advance-commercialization/</link>
		
		<dc:creator><![CDATA[Britt-Louise Rambäck]]></dc:creator>
		<pubDate>Mon, 30 Mar 2026 08:54:07 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">https://cellevate.com/?p=4790</guid>

					<description><![CDATA[LUND, Sweden – March 30, 2026 – Cellevate AB today announced the successful closing of a new financing round in February 2026, raising SEK 21.3 million from a combination of existing shareholders and new investors, including Almi Invest. The strong participation from both current and new investors reflects continued confidence in Cellevate’s strategy, execution capabilities,...]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph"><strong>LUND, Sweden – March 30, 2026</strong> – Cellevate AB today announced the successful closing of a new financing round in February 2026, raising SEK 21.3 million from a combination of existing shareholders and new investors, including Almi Invest.</p>



<p class="wp-block-paragraph">The strong participation from both current and new investors reflects continued confidence in Cellevate’s strategy, execution capabilities, and long-term value creation potential. The Board of Directors and management view this support as a clear validation of the company’s direction and its progress in advancing Cellevat3d® VAX nanofibers commercialization and scale up together with strategic partners and vaccine producers.</p>



<p class="wp-block-paragraph"><strong>For more information, please contact:<br></strong>Karsten Fjärstedt<br>Interim CEO, Cellevate<br>Email: karsten.fjarstedt@cellevate.com</p>



<p class="wp-block-paragraph"><strong>About Cellevate<br></strong>Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture solutions for cell and gene therapy and novel vaccines biomanufacturing. The company is ISO 9001:2015certified and has implemented GMP processes for production in clean room. The core nanotechnology, Cellevat3d<sup>®</sup> is a sustainable, deeptech innovation for the biopharmaceutical industry. This platform allows industrial-scale production of a new category of nanofiber cell culture systems – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to increased yield, productivity and process economy. Cellevat3d<sup>®</sup> nanofiber-based products are designed and validated as an integrated part of upstream bioprocessing solutions, from laboratory to large-scale production.</p>



<p class="wp-block-paragraph">For more information, please visit <a href="http://www.cellevate.com">www.cellevate.com</a>.</p>



<p class="wp-block-paragraph"><strong>About Almi Invest<br></strong>Almi Invest is Sweden’s most active startup investor and a state-owned, industry-independent venture capital company, with a substantial part of the portfolio within life science.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Cellevate announces leadership change</title>
		<link>https://cellevate.com/cellevate-announces-leadership-change/</link>
		
		<dc:creator><![CDATA[Britt-Louise Rambäck]]></dc:creator>
		<pubDate>Mon, 23 Mar 2026 08:55:26 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">https://cellevate.com/?p=4783</guid>

					<description><![CDATA[LUND, Sweden – March 23, 2026 – Cellevate today announces leadership change as CEO Laura Chirica moves on to new opportunities. The Board of Directors has appointed Karsten Fjärstedt as Interim CEO, effective immediately. The Board has initiated a search process for a permanent CEO and will announce a successor in due course. The Board...]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph"><strong>LUND, Sweden – March 23, 2026</strong> – Cellevate today announces leadership change as CEO Laura Chirica moves on to new opportunities. The Board of Directors has appointed Karsten Fjärstedt as Interim CEO, effective immediately.</p>



<p class="wp-block-paragraph">The Board has initiated a search process for a permanent CEO and will announce a successor in due course.</p>



<p class="wp-block-paragraph">The Board would like to thank Laura Chirica for her significant contributions to the company. During her tenure, she played an instrumental role in building the organization and advancing Cellevate’s strategy and financing, helping position the company as an innovator and emerging force in industrial bioprocessing for next-generation biotherapies. The Board wishes her continued success in her future endeavors.</p>



<p class="wp-block-paragraph">The Board is also pleased to welcome Karsten Fjärstedt as Interim CEO during this important phase of the company’s development. Karsten brings more than 30 years of experience from the bioprocessing industry, including senior leadership roles at Bio-Works and GE Healthcare. He has extensive expertise in commercialization, operations, and production, and a strong track record of scaling businesses within the bioprocessing sector.</p>



<p class="wp-block-paragraph"><strong>For more information, please contact:<br></strong>Uwe Gottschalk<br>Chairman of Cellevate Board of Directors<br>Email: <a href="mailto:uwe.gottschalk@keensight.com">uwe.gottschalk@keensight.com</a></p>



<p class="wp-block-paragraph"><strong>About Cellevate<br></strong>Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture solutions for cell and gene therapy and novel vaccines biomanufacturing. The company is ISO 9001:2015certified and has implemented GMP processes for production in clean room. The core nanotechnology, Cellevat3d® is a sustainable, deeptech innovation for the biopharmaceutical industry. This platform allows industrial-scale production of a new category of nanofiber cell culture systems – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to increased yield, productivity and process economy. Cellevat3d<sup>®</sup> nanofiber-based products are designed and validated as an integrated part of upstream bioprocessing solutions, from laboratory to large-scale production.</p>



<p class="wp-block-paragraph">For more information, please visit <a href="http://www.cellevate.com">www.cellevate.com</a>.<strong></strong></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Cellevate AB and InVitria Inc. enter strategic collaboration to advance upstream bioprocessing solutions for viral vaccine production</title>
		<link>https://cellevate.com/cellevate-ab-and-invitria-inc-enter-strategic-collaboration-to-advance-upstream-bioprocessing-solutions-for-viral-vaccine-production/</link>
		
		<dc:creator><![CDATA[Britt-Louise Rambäck]]></dc:creator>
		<pubDate>Tue, 10 Mar 2026 10:46:53 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">https://cellevate.com/?p=4769</guid>

					<description><![CDATA[LUND, Sweden – March 10, 2026 – Cellevate AB today announces a strategic collaboration agreement with InVitria, Inc., a U.S.-based leader in chemically defined, animal-component-free cell culture media and recombinant protein solutions. The collaboration will execute a joint development program integrating InVitria’s high-performance media with Cellevate’s Cellevat3d® nanofiber microcarrier platform. The program includes microcarrier screening,...]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph"><strong>LUND, Sweden – March 10, 2026</strong> – Cellevate AB today announces a strategic collaboration agreement with InVitria, Inc., a U.S.-based leader in chemically defined, animal-component-free cell culture media and recombinant protein solutions.</p>



<p class="wp-block-paragraph">The collaboration will execute a joint development program integrating InVitria’s high-performance media with Cellevate’s Cellevat3d<sup>®</sup> nanofiber microcarrier platform. The program includes microcarrier screening, process optimization, virus production studies, and scale-up activities aimed at generating performance data to support future commercial deployment in viral vaccine manufacturing.</p>



<p class="wp-block-paragraph">This partnership represents an important step in validating Cellevate’s technology within an integrated upstream workflow alongside a recognized U.S. media provider. By combining advanced nanofiber-based cell culture workflows with chemically defined media, the companies aim to deliver improved viral titers, enhanced scalability, reduced resource consumption, and significantly improved productivity at lower costs — key drivers for industrial vaccine production.</p>



<p class="wp-block-paragraph"><em>“This collaboration strengthens the commercial positioning of our Cellevat3d<sup>®</sup> platform by integrating it with complementary, industry-proven media solutions,”</em> said Laura Chirica, CEO of Cellevate. <em>“Generating industrially relevant performance data together with InVitria is an important milestone as we advance toward broader adoption and scale-up within vaccine manufacturing.”</em></p>



<p class="wp-block-paragraph"><em>“We are excited to collaborate with Cellevate to combine the potential of advanced nanofiber technology and chemically defined media. This partnership reflects our commitment to enabling more efficient and sustainable viral vaccine manufacturing processes,”</em> said Scott Deeter, CEO, InVitria, Inc.</p>



<p class="wp-block-paragraph">The results of the joint development program are expected to support future customer engagements and commercialization initiatives.</p>



<p class="wp-block-paragraph"><strong>For more information, please contact:<br></strong>Laura Chirica, PhDCEO Cellevate<br>Email: <a href="mailto:laura.chirica@cellevate.com">laura.chirica@cellevate.com</a><strong></strong></p>



<p class="wp-block-paragraph"><strong>About Cellevate<br></strong>Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture solutions for cell and gene therapy and novel vaccines biomanufacturing. The company is ISO 9001:2015certified and has implemented GMP processes for production in clean room. The core nanotechnology, Cellevat3d® is a sustainable, deeptech innovation for the biopharmaceutical industry. This platform allows industrial-scale production of a new category of nanofiber cell culture systems – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to increased yield, productivity and process economy. Cellevat3d<sup>®</sup> nanofiber-based products are designed and validated as an integrated part of upstream bioprocessing solutions, from laboratory to large-scale production.</p>



<p class="wp-block-paragraph">For more information, please visit <a href="http://www.cellevate.com">www.cellevate.com</a>.<strong></strong></p>



<p class="wp-block-paragraph"><strong>About InVitria<br></strong>InVitria is a global leader in the development and manufacture of high-performance blood-free cell culture and recombinant protein products designed to improve biomanufacturing and facilitate faster approval of life-changing therapies. The company provides unparalleled high-performance solutions for elimination of human and animal serum-derived raw materials in clinical manufacturing and commercial production of cell and gene therapies, vaccines, regenerative medicine, and medical devices. InVitria adheres to the FDA, and EMA regulations and offers cGMP and ISO compliant manufacturing capabilities scaled to meet growing global demand for chemically defined production of biologics.</p>



<p class="wp-block-paragraph">For more information, please visit <a href="http://www.invitria.com">www.invitria.com</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Cellevate selected to enter negotiations with EIC Fund for potential follow-on equity investment to support the company’s next growth phase in vaccine manufacturing</title>
		<link>https://cellevate.com/cellevate-selected-to-enter-negotiations-for-equity-investment-from-eic-fund/</link>
		
		<dc:creator><![CDATA[Britt-Louise Rambäck]]></dc:creator>
		<pubDate>Wed, 18 Feb 2026 14:26:01 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">https://cellevate.com/?p=4761</guid>

					<description><![CDATA[LUND, Sweden – February 18, 2026 – Cellevate today announces that the company has been selected to enter negotiations with the European Innovation Council (EIC) Fund regarding a potential follow-on equity investment, to be syndicated with new investors in a financing round planned for the second half of 2026. The financing will support Cellevate’s next...]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph"><strong>LUND, Sweden – February 18, 2026 </strong>– Cellevate today announces that the company has been selected to enter negotiations with the European Innovation Council (EIC) Fund regarding a potential follow-on equity investment, to be syndicated with new investors in a financing round planned for the second half of 2026.</p>



<p class="wp-block-paragraph">The financing will support Cellevate’s next growth phase in vaccine manufacturing, including production scale-up of the Cellevat3d® VAX nanofiber products, expanded evaluations with major vaccine manufacturers and strategic partners, industrial bioreactor integration in large scale, and international commercial expansion.</p>



<p class="wp-block-paragraph"><em>“We are proud to be one of 61 companies selected by the EIC following a highly competitive process. This recognition confirms the potential of our nanofiber technology to transform vaccine biomanufacturing by enabling &gt;10x higher viral titers, faster scale-up, and significantly improved production efficiency and sustainability. We look forward to the negotiation and due diligence process for this potential follow-on investment from EIC Fund and we are grateful for their support since the beginning of our industrial journey in 2022,”</em> says Laura Chirica, CEO of Cellevate.</p>



<p class="wp-block-paragraph">Further information will be communicated at a later stage.</p>



<p class="wp-block-paragraph"><strong>For more information, please contact:</strong><br>Laura Chirica, PhD<br>CEO Cellevate<br>Email: <a href="mailto:laura.chirica@cellevate.com">laura.chirica@cellevate.com</a></p>



<p class="wp-block-paragraph"><strong>About Cellevate</strong><br>Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture solutions for cell and gene therapy and novel vaccines biomanufacturing. The company is ISO 9001:2015 certified and has implemented GMP processes for production in clean room. The core nanotechnology, Cellevat3d® is a sustainable, deeptech innovation for the biopharmaceutical industry. This platform allows industrial-scale production of a new category of nanofiber cell culture systems – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to increased yield, productivity and process economy. Cellevat3d® nanofiber-based products are designed and validated as an integrated part of upstream bioprocessing solutions, from laboratory to large-scale production.<br><br>For more information, please visit <a href="http://www.cellevate.com">www.cellevate.com</a>.</p>



<p class="wp-block-paragraph"><strong>About EIC Fund</strong><br>The European Innovation Council Fund from the European Commission is a deep tech investor across all technologies. The EIC Fund aims to fill a critical financing gap, to support companies in the development and commercialisation of disruptive technologies. With its large network of capital providers and strategic partners it shares risk and crowds in market players. <br><br>More information: <a href="https://eic.ec.europa.eu/eic-fund_en" target="_blank" rel="noreferrer noopener">https://eic.ec.europa.eu/eic-fund_en</a></p>



<p class="wp-block-paragraph"></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Cellevate caps strong 2025 by achieving ISO 9001:2015 certification and implementing GMP production processes in new cleanroom</title>
		<link>https://cellevate.com/cellevate-caps-strong-2025-by-achieving-iso-90012015-certification-and-implementing-gmp-production-processes-in-new-cleanroom/</link>
		
		<dc:creator><![CDATA[Britt-Louise Rambäck]]></dc:creator>
		<pubDate>Tue, 16 Dec 2025 11:55:08 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">https://cellevate.com/?p=4751</guid>

					<description><![CDATA[LUND, Sweden – December 16, 2025 – Cellevate announces that it has achieved ISO 9001:2015 certification combined with GMP processes in cleanroom, marking a major milestone for Cellevate to becoming an industrial bioprocessing supplier. The certification reflects Cellevate’s dedication to delivering the highest standard of quality assurance throughout all its processes, from the business plan...]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph"><strong>LUND, Sweden – December 16, 2025</strong> – Cellevate announces that it has achieved ISO 9001:2015 certification combined with GMP processes in cleanroom, marking a major milestone for Cellevate to becoming an industrial bioprocessing supplier.</p>



<p class="wp-block-paragraph">The certification reflects Cellevate’s dedication to delivering the highest standard of quality assurance throughout all its processes, from the business plan and company management to research and development, production, sales and marketing, product delivery and customer support.</p>



<p class="wp-block-paragraph">“<em>Quality assurance is the responsibility of every Cellevate employee,” </em>said Annika Andersson in charge of QA/RA at Cellevate. <em>“Our mission has been from the start to bring to market cutting-edge, state-of-the-art products that truly meet the needs of our customers. In earning this certification, we are driven to not only adhere to our already high-quality assurance standards, but to continually improve upon them</em>.”</p>



<p class="wp-block-paragraph">In parallel with achieving ISO 9001 certification, Cellevate has completed and validated a new cleanroom at its facility in Lund. The cleanroom is dedicated to the production of the company’s commercial portfolio, Cellevat3d® nanofiber products, supporting the increasing demand from global distributors, biopharmaceutical companies, and CDMOs.</p>



<p class="wp-block-paragraph">The cleanroom was designed and installed by Guardtech Cleanrooms (UK) using the modular ISOPOD construction platform. This cost-efficient approach enabled rapid installation while allowing the facility to be easily expanded or reconfigured as demand grows and commercial volumes increase. The cleanroom has been validated according to ISO 14644, ensuring compliance with international standards for air cleanliness, environmental control, and contamination management.</p>



<p class="wp-block-paragraph"><em>“Securing ISO 9001 certification is more than a quality milestone. It reflects our commitment to operational excellence and to supporting our customers with the highest level of reliability as we scale and intensify commercial operations,” </em>said Laura Chirica, CEO at Cellevate.<em> “Combined with the new cleanroom, we now have a robust and scalable foundation for expanding manufacturing capacity and implementing GMP-ready processes for commercial volumes. These new advancements strengthen Cellevate’s position as a trusted partner and supplier to customers and collaborators across the biopharmaceutical and bioprocessing industry.”</em></p>



<figure class="wp-block-image size-medium"><img fetchpriority="high" decoding="async" width="243" height="300" src="https://cellevate.com/wp-content/uploads/2025/12/ISO-9001_2015-243x300.jpg" alt="" class="wp-image-4726" srcset="https://cellevate.com/wp-content/uploads/2025/12/ISO-9001_2015-243x300.jpg 243w, https://cellevate.com/wp-content/uploads/2025/12/ISO-9001_2015-831x1024.jpg 831w, https://cellevate.com/wp-content/uploads/2025/12/ISO-9001_2015-768x946.jpg 768w, https://cellevate.com/wp-content/uploads/2025/12/ISO-9001_2015-1246x1536.jpg 1246w, https://cellevate.com/wp-content/uploads/2025/12/ISO-9001_2015-1662x2048.jpg 1662w, https://cellevate.com/wp-content/uploads/2025/12/ISO-9001_2015-600x739.jpg 600w, https://cellevate.com/wp-content/uploads/2025/12/ISO-9001_2015.jpg 1967w" sizes="(max-width: 243px) 100vw, 243px" /></figure>



<p class="wp-block-paragraph"><strong>For more information, please contact:</strong><br>Laura Chirica, PhD<br>CEO Cellevate<br>Email: <a href="mailto:laura.chirica@cellevate.com">laura.chirica@cellevate.com</a></p>



<p class="wp-block-paragraph"><strong>About Cellevate</strong><br>Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture solutions for cell and gene therapy and novel vaccines biomanufacturing. The company is ISO 9001:2015 certified and has implemented GMP processes for production in clean room. The core nanotechnology, Cellevat3d® is a sustainable, deeptech innovation for the biopharmaceutical industry. This platform allows industrial-scale production of a new category of nanofiber cell culture systems – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to increased yield, productivity and process economy. Cellevat3d® nanofiber-based products are designed and validated as an integrated part of upstream bioprocessing solutions, from laboratory to large-scale production.<br><br>For more information, please visit <a href="http://www.cellevate.com">www.cellevate.com</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Cellevate to announce major advances in yield and scalability of viral vaccine production at World Vaccine Congress Europe with global launch of Cellevat3d® VAX nanofiber microcarriers</title>
		<link>https://cellevate.com/cellevate-to-announce-major-advances-in-yield-and-scalability-of-viral-vaccine-production-at-world-vaccine-congress-europe-with-global-launch-of-cellevat3d-vax-nanofiber-microcarriers/</link>
		
		<dc:creator><![CDATA[Britt-Louise Rambäck]]></dc:creator>
		<pubDate>Mon, 13 Oct 2025 09:39:17 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">https://cellevate.com/?p=4675</guid>

					<description><![CDATA[LUND, Sweden, October 13, 2025 – Cellevate AB today announced the upcoming global launch at the World Vaccine Congress Europe in Amsterdam, October 14–16, 2025 of Cellevat3d® VAX nanofiber microcarriers for adherent cell-based viral vaccine production. Join our launch event and company presentation on October 16 at 12:30 in the Manufacturing Technologies track, where CTO...]]></description>
										<content:encoded><![CDATA[
<ul class="wp-block-list">
<li><strong>>13-fold higher infectious viral vaccine titers in Vero cell cultures</strong> compared to industry-standard microcarriers</li>



<li><strong>11.4-fold higher infectious enterovirus vaccine titers</strong> demonstrated in HEK293T cultures in an independent study conducted by Intravacc B.V. (CDMO, The Netherlands)</li>



<li>Formation of <strong>homogeneous, high-density 3D spheroid cultures</strong>, <strong>supporting efficient virus propagation, high cell specific viral productivity and scale up</strong></li>



<li><strong>85% reduction in cost of production for viral vaccine processes compared to current industry-standard</strong></li>
</ul>



<p class="wp-block-paragraph"><strong>LUND, Sweden, October 13, 2025</strong> – Cellevate AB today announced the upcoming global launch at the <strong>World Vaccine Congress Europe in Amsterdam, October 14–16, 2025</strong> of Cellevat3d® VAX nanofiber microcarriers for adherent cell-based viral vaccine production. Join our launch event and company presentation on October 16 at 12:30 in the Manufacturing Technologies track, where CTO Dr. Christel Fenge will present the outstanding performance data.<br><br>Adherent cell-based viral vaccine production traditionally relies on bead-based microcarriers, roller bottles, cell stacks, and fixed-bed bioreactors. While widely used, these methods are limited in scalability, cost-efficiency, and process robustness. The Cellevat3d® VAX product addresses these challenges by introducing sustainable, cellulose-derived nanofibers supporting the expansion of adherent cell cultures in conventional stirred-tank bioreactors. This breakthrough enables seamless process transfer, improved scalability, and significantly higher viral vaccine yields enhancing overall manufacturing efficiency.  </p>



<p class="wp-block-paragraph"><em>&#8220;With this new product launch, Cellevate demonstrates the versatility of its next-generation, nanofiber-based microcarrier platform across all areas of adherent cell cultivation. Breakthrough medicine requires breakthrough innovations in biomanufacturing and Cellevate will keep delivering on that paradigm,&#8221; </em>commented Dr. Uwe Gottschalk, Chairman of the Board, Cellevate.&nbsp;</p>



<p class="wp-block-paragraph"><em>“The key challenges in vaccine manufacturing are to bring new vaccines to the market faster and at lower production costs, only achievable through implementation of disruptive technologies. With more than 13-fold increase in viral vaccine titers, Cellevat3d® VAX nanofiber microcarriers have the potential to transform the way viral vaccines are manufactured and to accelerate vaccine development and patient access,” </em>said Laura Chirica, CEO, Cellevate.</p>



<p class="wp-block-paragraph">For more information about Cellevat3d® VAX nanofiber microcarriers, please visit: <a href="https://cellevate.com/cellevat3d-products/cellevat3d-nanofiber-microcarriers-in-viral-vaccine-production/">www.cellevate.com</a></p>



<p class="wp-block-paragraph"><strong>For more information, please contact:</strong><br>Laura Chirica, PhD<br>CEO Cellevate<br>Email: <a href="mailto:laura.chirica@cellevate.com">laura.chirica@cellevate.com</a></p>



<p class="wp-block-paragraph"><strong>About Cellevate</strong><br>Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture solutions for cell and gene therapy and novel vaccines biomanufacturing. The core nanotechnology, Cellevat3d® is a sustainable, deeptech innovation for the biopharmaceutical industry. This platform allows industrial-scale production of a new category of nanofiber cell culture systems – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to increased yield, productivity and process economy. Cellevat3d® nanofiber-based products are designed and validated as an integrated part of upstream bioprocessing solutions, from laboratory to large-scale production.</p>



<p class="wp-block-paragraph">For more information, please visit <a href="http://www.cellevate.com">www.cellevate.com</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>More than 10-fold enhanced viral vaccine production titers using the novel Cellevat3d® nanofiber microcarriers</title>
		<link>https://cellevate.com/more-than-10-fold-enhanced-viral-vaccine-production-titers-using-the-novel-cellevat3d-nanofiber-microcarriers/</link>
		
		<dc:creator><![CDATA[Britt-Louise Rambäck]]></dc:creator>
		<pubDate>Tue, 19 Aug 2025 07:54:56 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">https://cellevate.com/?p=4477</guid>

					<description><![CDATA[LUND, Sweden, August 19, 2025 – Cellevate AB publishes today results from their vaccine production validation program that is designed to evaluate and validate the performance of the cell culture products based on proprietary nanotechnology Cellevat3d®. In internal studies, the data demonstrated that Vero cells cultured on Cellevat3d® nanofiber microcarriers rapidly formed dense and uniform...]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph"><strong>LUND, Sweden, August 19, 2025</strong> – Cellevate AB publishes today results from their vaccine production validation program that is designed to evaluate and validate the performance of the cell culture products based on proprietary nanotechnology Cellevat3d®.</p>



<p class="wp-block-paragraph">In internal studies, the data demonstrated that Vero cells cultured on Cellevat3d® nanofiber microcarriers rapidly formed dense and uniform 3D spheroids, reaching high, viable cell densities. Importantly, the nanofiber-based microcarrier cell cultures successfully produced high infectious titers of enterovirus A71 (EV71).</p>



<p class="wp-block-paragraph">In parallel, Intravacc B.V., a leading European CDMO specializing in vaccine manufacturing, conducted an independent benchmarking study using HEK 293T cells. The study compared Cellevat3d® nanofiber microcarriers with industry-standard microcarriers in enterovirus production. The outcome was compelling: a 11.4-fold increase in infectious virus titers and a 17-fold improvement in cell-specific virus yield using the nanofiber-based 3D cultures. These findings further validate the platform’s performance across diverse cell systems and production models.</p>



<p class="wp-block-paragraph"><em>“We are thrilled by these results, first and foremost because vaccine development and production are challenged by cost and time. By implementing Cellevat3d® nanofiber products, the cost of vaccine production could be reduced up to 85% compared to current traditional processes. The cost reduction is based on exceptional yield improvements, process simplicity, robust scalability, faster bioprocessing, reduced waste and water use, and improved process sustainability, all values provided by Cellevat3d® nanofiber products,” </em>said Laura Chirica, CEO of Cellevate. <br><em>&#8220;Secondly, the flexibility of Cellevat3d®</em> <em>nanotechnology allows us to develop and commercialize new products for critical applications in advanced therapies production. Next in line is the Cellevat3d® VAX nanofiber product for vaccine production, to be launched at World Vaccine Congress in October 2025 in Amsterdam.”</em></p>



<p class="wp-block-paragraph">A full summary of the performance data is available in a new Application Note at: <img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f517.png" alt="🔗" class="wp-smiley" style="height: 1em; max-height: 1em;" /> <a href="https://cellevate.com/cellevat3d-products/cellevat3d-vax-nanofiber-microcarriers/">www.cellevate.com</a>.</p>



<p class="wp-block-paragraph"><strong>For more information, please contact:</strong><br>Laura Chirica, PhD<br>CEO Cellevate<br>Email: <a href="mailto:laura.chirica@cellevate.com">laura.chirica@cellevate.com</a></p>



<p class="wp-block-paragraph"><strong>About Cellevate</strong><br>Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture solutions for cell- and gene therapy and novel vaccines biomanufacturing. The core nanotechnology, Cellevat3d® is a sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of a new category of nanofiber cell culture systems – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to increased yield, productivity and process economy. Cellevat3d® nanofiber-based products are designed and validated as an integrated part of upstream bioprocessing solutions, from laboratory to large-scale production.</p>



<p class="wp-block-paragraph">For more information, please visit <a href="http://www.cellevate.com">www.cellevate.com</a>.</p>



<p class="wp-block-paragraph"><strong>About Intravacc</strong><br>Intravacc, located at Utrecht Science Park Bilthoven in the Netherlands, is a leading global contract development and manufacturing organization (CDMO) of innovative vaccines against infectious diseases. As an established independent CDMO with an outstanding track record in vaccine development and vaccine technologies, Intravacc has transferred its technology related to polio vaccines, measles vaccines, DPT vaccines, Hib vaccines and influenza vaccines around the world. Around 40% of childhood disease vaccines are based on Intravacc’s proprietary technology. Intravacc offers a wide range of expertise to develop vaccine from concept to Phase I/II clinical studies for partners around the world, including universities, public health organizations (WHO, Bill &amp; Melinda Gates Foundation), biotech and pharmaceutical companies.</p>



<p class="wp-block-paragraph">For more information, please visit&nbsp;<a href="https://www.intravacc.nl/" target="_blank" rel="noreferrer noopener">Intravacc B.V.</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Cellevate, Fraunhofer IBMT and OLS consortium awarded EUR 1 million Eurostar grant for large scale production of induced pluripotent stem cells</title>
		<link>https://cellevate.com/cellevate-fraunhofer-ibmt-and-ols-consortium-awarded-eur-1-million-eurostar-grant-for-large-scale-production-of-induced-pluripotent-stem-cells/</link>
		
		<dc:creator><![CDATA[Britt-Louise Rambäck]]></dc:creator>
		<pubDate>Fri, 25 Apr 2025 07:56:39 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">https://cellevate.com/?p=4161</guid>

					<description><![CDATA[LUND, Sweden, April 25, 2025 – Cellevate AB, Fraunhofer IBMT (Institute for Biomedical Engineering), and the German bioreactor company OLS (Omni Life Science) have been awarded a EUR 1 million grant through the Eurostar program for large scale production of iPSCs (induced pluripotent stem cells). The project will run for three years and aims to...]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph"><strong>LUND, Sweden, April 25, 2025 – </strong>Cellevate AB, <a href="https://www.ibmt.fraunhofer.de/en.html">Fraunhofer IBMT (Institute for Biomedical Engineering)</a>, and the German bioreactor company <a href="https://www.ols-bio.com/">OLS (Omni Life Science)</a> have been awarded a EUR 1 million grant through the Eurostar program for large scale production of iPSCs (induced pluripotent stem cells). The project will run for three years and aims to validate the use of Cellevat3d<sup>®</sup> nanofiber microcarriers for large scale production of iPSCs in the OLS bioreactor including benchmarking data vs market standard processes. Fraunhofer IBMT will play an important role in designing and performing the studies through its leading expertise in applied stem cell research and biomedical engineering, while OLS brings specialized knowhow in cutting-edge bioreactor technologies and cell culture systems.</p>



<p class="wp-block-paragraph">The global iPSC market is expected to grow from USD 677 million in 2023 to USD 1.1 billion by 2030, with a CAGR of 8.8%. iPSCs are a promising cell source for curative therapies, disease modeling, and drug discovery. These cells can differentiate into a wide variety of cell types, including neurons and cardiomyocytes, which is not possible for many other cell types, such as mesenchymal stem cells (MSCs).</p>



<p class="wp-block-paragraph">Laura Chirica, CEO of Cellevate, stated: <em>“We are very grateful for receiving funding from Eurostar and we are looking forward to collaborating with Fraunhofer IBMT and OLS on this exciting project. </em><em>Human induced pluripotent stem cells exhibit significant potential for regenerative medical treatments due to their pluripotency and proliferation capacity. However, the large-scale production required for allogeneic therapies necessitates efficient and scalable culture systems. The newly launched Cellevat3d<sup>®</sup> nanofiber microcarriers product with their extremely large surface area and the three-dimensional scale-up that is fast and easy, could solve the challenges for the iPSCs large-scale production in suspension bioreactor cultures.”</em></p>



<p class="wp-block-paragraph"><strong>For more information, please contact:</strong><br>Laura Chirica, PhD<br>CEO Cellevate<br>Email: <a href="mailto:laura.chirica@cellevate.staging.rackfish.net">laura.chirica@cellevate.staging.rackfish.net</a></p>



<p class="wp-block-paragraph"><strong>About Cellevate</strong><br>Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture solutions for cell- and gene therapy and novel vaccines biomanufacturing. The core nanotechnology, Cellevat3d® is a sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of a new category of nanofiber cell culture systems – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to increased yield, productivity and process economy. Cellevat3d® nanofiber-based products are designed and validated as an integrated part of upstream bioprocessing solutions, from laboratory to large-scale production.<br><br>For more information, please visit <a href="http://www.cellevate.staging.rackfish.net">www.cellevate.staging.rackfish.net</a>.</p>



<p class="wp-block-paragraph"><strong>About the Fraunhofer Institute for Biomedical Engineering IBMT</strong><br>The development of new  drugs and personalised diagnostic and therapeutic approaches are among the most promising topics of the future. The Fraunhofer IBMT is responding to this trend by developing innovative upscaling and cryopreservation strategies to optimise the efficiency and reproducibility of stem cell processes. Through the coordination of the imi project EBiSC2 &#8211; The European Bank for iPS Cells &#8211; and the global stem cell registry hPSCreg, the Fraunhofer IBMT has a unique infrastructure for the development of new cell models as well as drug and toxicity assays. In parallel, peripheral technologies in the field of intelligent sensors, bioinformatic data applications and cryobiotechnology are being developed. The most important criterion here is the generation and cryopreservation of large quantities of stem cells with consistently high quality.</p>



<p class="wp-block-paragraph">For more information, please visit <a href="http://www.ibmt.fraunhofer.de">www.ibmt.fraunhofer.de</a>.</p>



<p class="wp-block-paragraph"><strong>About OLS (Omni Life Science)</strong><br>At OMNI Life Science, we envision a world of cell research technologies for life sciences and biotechnology. Our commitment is to empower scientists in academia, industry and clinical sector with reliable, high-quality tools and solutions that address the needs of today´s and future cell research labs.<br>OMNI Life Science specializes in offering advanced products as instruments, media, reagents, and consumables for Cell Counting, Cell Culture, Imaging, Flow Cytometry and Cell Analysis.<br>As a global player in the life sciences industry, OMNI Life Science is dedicated to making a positive impact on cell research worldwide. Join us on our journey in cell research.</p>



<p class="wp-block-paragraph">Your Partner in Cell Research |&nbsp;&nbsp;<a href="http://www.ols-bio.com/">www.ols-bio.com</a>.<strong></strong></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Cellevate hosts Global Webinar presenting latest data and process economy savings in viral vector production with Cellevat3d® nanofiber microcarriers – April 1, 2025 at 17:00 CET</title>
		<link>https://cellevate.com/cellevate-hosts-global-webinar-presenting-latest-data-and-process-economy-savings-in-viral-vector-production-with-cellevat3d-nanofiber-microcarriers-april-1-2025-at-1700-cet/</link>
		
		<dc:creator><![CDATA[Britt-Louise Rambäck]]></dc:creator>
		<pubDate>Mon, 17 Mar 2025 09:47:43 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">https://cellevate.com/?p=4058</guid>

					<description><![CDATA[LUND, Sweden, March 17, 2025 – Following the interest since the launch of the world’s first nanofiber-based cell culture systems at the end of 2024, Cellevate is pleased to announce a 2nd webinar on the productivity increases and resulting cost reductions based on a process economy model for large-scale gene therapy production. Held in collaboration...]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph"><strong>LUND, Sweden, March 17, 2025 </strong>– Following the interest since the launch of the world’s first nanofiber-based cell culture systems at the end of 2024<strong>, </strong>Cellevate is pleased to announce a 2<sup>nd</sup> webinar on the productivity increases and resulting cost reductions based on a process economy model for large-scale gene therapy production. Held in collaboration with Cell &amp; Gene Therapy Insights, the webinar will present the latest data comparing Cellevat3d®nanofiber productswith traditional bead-based microcarriers. The model outlines the potential of Cellevat3d® nanofiber microcarriers to lower gene therapy production costs by up to 70% per dose by providing greater than 90% transfection efficiencies, 3x higher viral vector titer yields, fast and easy scale up and enzyme free passaging.</p>



<p class="wp-block-paragraph">Presenting the data in the webinar will be Dr. Christel Fenge (Chief Technology Officer, Cellevate), Geddy Hamblen (Application Manager, Cellevate), and Rob Noel (Commercialization Consultant, 55Biomarkets).</p>



<p class="wp-block-paragraph"><strong>Webinar Title:</strong> <strong>Cost reduction of viral vector processes using 3D nanofiber-based cell culture systems in upstream bioprocessing<br>Date:</strong> Tuesday, April 1, 2025<br><strong>Time:</strong> 08:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST</p>



<p class="wp-block-paragraph"><a>For more </a><a href="https://www.workcast.com/register?cpak=8525939050202835"><strong>details about the webinar and to register</strong></a><strong>.</strong></p>



<p class="wp-block-paragraph"><strong>For more information, please contact:</strong><br>Laura Chirica, PhD<br>CEO Cellevate<br>Email: <a href="mailto:laura.chirica@cellevate.staging.rackfish.net">laura.chirica@cellevate.staging.rackfish.net</a></p>



<p class="wp-block-paragraph"><strong>About Cellevate</strong><br>Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture solutions for cell- and gene therapy and novel vaccines biomanufacturing. The core nanotechnology, Cellevat3d® is a sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of a new category of nanofiber cell culture systems – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to increased yield, productivity and process economy. Cellevat3d® nanofiber-based products are designed and validated as an integrated part of upstream bioprocessing solutions, from laboratory to large-scale production.<br><br>For more information, please visit <a href="http://www.cellevate.staging.rackfish.net">www.cellevate.staging.rackfish.net</a>.</p>



<p class="wp-block-paragraph"></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Cellevate strengthens management team with the appointment of Dr. Christel Fenge as Chief Technology Officer</title>
		<link>https://cellevate.com/cellevate-strengthens-management-team-with-the-appointment-of-dr-christel-fenge-as-chief-technology-officer/</link>
		
		<dc:creator><![CDATA[Britt-Louise Rambäck]]></dc:creator>
		<pubDate>Wed, 12 Mar 2025 09:11:11 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">https://cellevate.com/?p=4048</guid>

					<description><![CDATA[Lund, Sweden, 12 March 2025 &#8211; Cellevate AB, an innovative biotech company developing next-generation cell culture solutions to revolutionize biomanufacturing, is pleased to announce the appointment of Dr. Christel Fenge as Chief Technology Officer (CTO) and member of the management team. Dr. Fenge, who has served as a Strategic Advisor to Cellevate since June 2024,...]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph"><strong>Lund, Sweden, 12 March 2025</strong> &#8211; Cellevate AB, an innovative biotech company developing next-generation cell culture solutions to revolutionize biomanufacturing, is pleased to announce the appointment of Dr. Christel Fenge as Chief Technology Officer (CTO) and member of the management team.</p>



<p class="wp-block-paragraph">Dr. Fenge, who has served as a Strategic Advisor to Cellevate since June 2024, brings over 30 years of experience in leadership roles within the bioprocessing and biopharmaceutical industries. Previous positions include VP, R&amp;D Bioprocess at Cytiva and VP, Marketing &amp; Product Management at Sartorius, overseeing upstream and downstream development and commercialization. This expertise will be instrumental in scaling up Cellevate’s groundbreaking nanofiber-based cell culture products.</p>



<p class="wp-block-paragraph">“I am delighted to take on the role of CTO at Cellevate,” says Dr. Christel Fenge. “The company’s commercially available nanofiber-based cell culture systems have already shown great potential in biomanufacturing, and I look forward to supporting the team as we now have moved into commercialization and scale-up.”</p>



<p class="wp-block-paragraph">“Bringing Dr. Fenge into the management team strengthens our ability to accelerate the commercialization and the strategic partnerships with customers and turnkey solution providers in bioprocessing,” says Laura Chirica, CEO of Cellevate. “Her deep expertise in upstream bioprocessing, combined with strategic leadership, will be invaluable as we continue to commercialize and implement Cellevat3d® nanofiber cell culture solutions in new therapeutic large-scale applications, develop new product families and position our company as a proven provider in this industry.”</p>



<p class="wp-block-paragraph">More information about <a href="https://cellevate.com/about/management-team/">Cellevate’s management team</a> can be found on our website.</p>



<p class="wp-block-paragraph"><strong>For more information, please contact:</strong><br>Laura Chirica, PhD<br>CEO Cellevate<br>Email: <a href="mailto:laura.chirica@cellevate.staging.rackfish.net">laura.chirica@cellevate.staging.rackfish.net</a></p>



<p class="wp-block-paragraph"><strong>About Cellevate</strong><br>Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture solutions for cell- and gene therapy and novel vaccines biomanufacturing. The core nanotechnology, Cellevat3d<sup>®</sup> is a sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of a new category of nanofiber cell culture systems – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to increased yield, productivity and process economy. Cellevat3d<sup>®</sup> nanofiber-based products are designed and validated as an integrated part of upstream bioprocessing solutions, from laboratory to large-scale production.<br><br>For more information, please visit <a href="http://www.cellevate.staging.rackfish.net">www.cellevate.staging.rackfish.net</a>.</p>



<p class="wp-block-paragraph"></p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>

<!--
Performance optimized by W3 Total Cache. Learn more: https://www.boldgrid.com/w3-total-cache/?utm_source=w3tc&utm_medium=footer_comment&utm_campaign=free_plugin

Page Caching using Disk: Enhanced 

Served from: cellevate.com @ 2026-11-18 14:40:37 by W3 Total Cache
-->